Pharmacological prophylaxis of chronic migraine: A review of double-blind placebo-controlled trials

Research output: Contribution to journalArticlepeer-review

Abstract

Chronic migraine is an important public health problem. The aim of treatment should be to reduce migraine frequency and its negative impact on functioning, as well as to limit the use of acute medications. These goals may be accomplished by introducing effective prophylaxis. The aim of the present article is to critically review the published evidence on the pharmacological prophylaxis of chronic migraine, analysing published double-blind, placebo- controlled studies on adult patients. The results of the review indicate that tizanidine, gabapentin, valproic acid, and particularly topiramate are effective prophylactics against chronic migraine, with improvements in several endpoints that were significantly superior to those achieved by placebo. However, the different results found by different trials, as well as several methodological problems inherent in the trials, suggest the need for further research to provide clear indications from large, multicentre, controlled trials with homogeneous inclusion criteria and adequate endpoints.

Original languageEnglish
JournalNeurological Sciences
Volume31
Issue numberSUPPL.1
DOIs
Publication statusPublished - Jun 2010

Keywords

  • Chronic migraine (CM)
  • Double-blind placebo-controlled trials
  • Prophylaxis

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Fingerprint Dive into the research topics of 'Pharmacological prophylaxis of chronic migraine: A review of double-blind placebo-controlled trials'. Together they form a unique fingerprint.

Cite this